Answers are grounded in this paper and cite their sources.
A case report reveals successful tofacitinib treatment for facial eosinophilic annular erythema in a patient with rheumatoid arthritis, suggesting new therapeutic avenues.
We report a case of a 67-year-old man with rheumatoid arthritis (RA) presenting with symmetrical annular plaques confined to the face. Histopathology demonstrated dense dermal eosinophilia without flame figures, consistent with eosinophilic annular erythema (EAE). Unlike the typical truncal distribution, lesions were limited to the face, a presentation reported in approximately 3% of cases. The patient was successfully treated with tofacitinib, a Janus kinase (JAK) inhibitor. This report illustrates a rare facial variant of EAE and supports the efficacy of JAK inhibition in patients with concurrent RA.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: